This study is in progress, not accepting new patients
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- start:end: about
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Fulcrum Therapeutics
- ID
- NCT05397470
- Phase
- Phase 3 Facioscapulohumeral Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- About 260 people participating
- Last Updated